Small Molecule Fibroblast Reprogramming for Stable Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for converting human fibroblasts into neural stem cells often rely on introducing foreign genes, which can lead to genomic instability and tumorigenesis, and are inefficient in producing sufficient amounts of genetically stable neural stem cells for therapeutic use.
Innovation Solution
A method involving culturing human fibroblasts in a medium containing Thiazovivin, Valproic acid, Purmorphamine, A8301, and CHIR99021 to produce neural stem cells without introducing foreign genes, ensuring genetic stability and sufficient proliferation for transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If foreign genes are introduced into human fibroblasts to convert them into neural stem cells, then neural stem cells can be produced, but genomic instability and tumorigenesis occur
Solution Approach 1:
The invention extracts and eliminates the harmful element (foreign gene introduction) from the reprogramming process. Instead of using viral vectors or plasmids to introduce foreign genes, the patent uses small-molecule compounds that directly induce transcription factor expression within the fibroblast's own genome, thereby achieving neural stem cell conversion without genomic integration and avoiding tumorigenesis
Solution Approach 2:
The invention substitutes the mechanical/genetic approach (foreign gene introduction via viral vectors) with a chemical approach (small-molecule compound treatment). The small molecules act as chemical inducers that trigger endogenous transcription factors to drive the conversion process, replacing the need for physical gene delivery systems and eliminating associated genomic instability risks
2Productivity
If viral systems are used to introduce transcription factors into fibroblasts, then neural stem cells can be induced, but mutations occur due to random integration
Solution Approach 1:
The invention removes the viral vector system entirely from the process. Instead of using lentiviral or retroviral vectors that randomly integrate into the genome, the patent employs small-molecule compounds that transiently activate endogenous transcription factors without any genomic integration, thereby eliminating the source of random mutations while maintaining neural stem cell induction capability
Solution Approach 2:
The invention introduces small-molecule compounds as intermediary substances that mediate the conversion process. These compounds act as chemical messengers that bind to and activate transcription factors or signaling pathways, serving as a safe intermediary that achieves the desired cellular reprogramming without the harmful direct genomic integration of viral systems
3Reliability
If plasmids or proteins are used to avoid viral integration, then mutations are reduced, but conversion efficiency becomes too low for therapeutic use
Solution Approach 1:
The invention optimizes multiple parameters of the small-molecule treatment protocol, including compound concentrations, treatment duration, sequential addition timing, and combination ratios of different small molecules. By systematically adjusting these parameters, the patent achieves both high conversion efficiency (suitable for therapeutic applications) and maintained genomic stability, overcoming the limitation of low efficiency associated with non-viral methods
Data Source
AI summary
The present invention relates to a method of converting human fibroblasts into neural stem cells, and more particularly, to a method of directly converting human fibroblasts into neural stem cells using only a combination of small-molecule compounds without any introduction of a foreign gene, and to the use of the neural stem cells. The method of directly converting human fibroblasts into neural stem cells using only small-molecule compounds without any introduction of a foreign gene makes it possible to obtain genetically stable neural stem cells in an amount sufficient for use in cell therapy by deriving them from human fibroblasts. The neural stem cells obtained according to the method of the present invention can differentiate into functional neural cells and are not tumorigenic. Thus, these neural stem cells are useful as cellular therapeutic agents for treatment of brain diseases.